Stocktoria
Travere Therapeutics, Inc. TVTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2003-07-23
Travere Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M | $131.8M | $198.3M | $175.3M | $164.2M | $154.9M | $133.6M |
| R&D expense | — | — | — | $7.5M | — | — | $141.0M | $123.8M | $78.2M | $70.8M |
| SG&A expense | $337.2M | $264.1M | $265.5M | $197.5M | $126.3M | $135.8M | $129.0M | $103.7M | $101.3M | $91.9M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M | -$199.4M | -$176.2M | -$137.4M | -$80.0M | -$53.8M | -$58.2M |
| Interest expense | — | — | $11.3M | $11.0M | $19.7M | $19.1M | $18.8M | $9.8M | $4.4M | $4.7M |
| Income tax | $988,000 | $120,000 | $223,000 | $313,000 | $409,000 | -$19.4M | -$21,000 | $811,000 | $1.4M | -$9.7M |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M | -$180.1M | -$169.4M | -$146.4M | -$102.7M | -$59.7M | -$47.9M |
| EPS (diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 | $-1.54 | $-1.29 |
| Operating cash flow | $37.8M | -$237.5M | -$325.4M | -$260.8M | -$76.2M | -$42.7M | -$58.2M | -$25.0M | $7.4M | -$3.4M |
| Free cash flow | — | — | -$326.0M | -$261.0M | -$81.3M | -$49.5M | -$58.4M | -$25.7M | $6.5M | -$4.9M |
| Cash & equivalents | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M | $84.8M | $62.4M | $102.9M | $99.4M | $41.0M |
| Inventory | $36.2M | $41.9M | $9.4M | $4.5M | $7.3M | $7.6M | $6.1M | $5.6M | $5.4M | $2.8M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M | $607.4M | $604.8M | $709.2M | $520.3M | $525.3M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M | $396.2M | $383.6M | $390.9M | $227.2M | $217.5M |
| Shareholders' equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M | $211.2M | $221.2M | $318.3M | $293.1M | $307.8M |
Growth · year-over-year · Revenue CAGR 15.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +110.5% | +60.5% | +32.7% | -17.0% | -33.5% | +13.1% | +6.8% | +6.0% | +16.0% | — |
| Net income growth | — | — | — | — | — | — | — | — | — | -140.9% |
| EPS growth | — | — | — | — | — | — | — | — | — | -140.7% |
| Free cash flow growth | — | — | — | — | — | — | — | -494.2% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.